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APC = adenomatous polyposis coli; CK2 = casein kinase 2; GSK3 = glycogen synthase kinase 3; LTR = long terminal repeat; MMTV = mouse
mammary tumor virus; WAP = whey acidic protein.
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Setting the stage
β-Catenin was originally identified as a component of
cell–cell adhesion complexes that are composed of cad-
herins, α-catenin and β-catenin, and actin. It became clear
during the past decade that β-catenin is also a down-
stream signaling molecule in the Wnt signaling pathway
and it controls transcription in concert with TCF/LEF pro-
teins (reviewed in [1]). Derailing this signaling pathway
can result in developmental defects or in the neoplastic
transformation of cells (Tables 1 and 2). For example, over-
expression of β-catenin induces an additional embryonic
axis in Xenopus laevis [2]. Also, ablation of the β-catenin
gene in the mouse resulted in a lack of mesoderm, a lack
of embryonic lethality [3] and an absence and/or misloca-
tion of anterior markers at embryonic day 5.5 [4]. In brain
and craniofacial development, β-catenin-null neural crest
cells fail to form the connecting parts between the cranial
ganglia and the hindbrain, and also fail to form cranial
skeletal structures [5].
These experiments demonstrated that β-catenin consti-
tutes an essential switch in the establishment of the verte-
brate body plan. On the other hand, gain-of-function
mutations within β-catenin that generate stabilized
β-catenin are well known in cancers of the colon, the liver,
the ovary, and the endometrium (reviewed in [6]).
Although stabilizing mutations in β-catenin are rarely
observed in breast cancer [7], 40% of breast cancers
overexpress cyclin D1 and almost of all of them (92%)
also had high levels of active β-catenin [8]. This suggests
that elevated β-catenin levels correlate with mammary
tumorigenesis.
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Abstract
Mutations and deletions that result in the stabilization of β-catenin are frequently found in a number of
tumors, including those of the colon, the liver and the ovary, but are less frequently found in breast
cancer. To investigate and understand the molecular nature of cell-specific β-catenin signaling,
experimental mouse genetics has been employed extensively. Gain-of-function and loss-of-function
mutations have provided evidence that β-catenin plays essential roles in development and
tumorigenesis. Specifically, the Wnt/β-catenin signaling pathway controls cell fate decisions
throughout development, and a unique role in differentiated epithelia has emerged. Not only β-catenin,
but also the activation of other components of this pathway in differentiated mammary epithelium and
prostate epithelium of transgenic mice can induce neoplasias and transdifferentiation to squamous
metaplasias. This suggests that the Wnt/β-catenin pathway is dominant over existing differentiation
programs and can impose an epidermal fate or neoplasias onto a variety of cell types. Although there is
evidence for a contextual specificity of the Wnt signaling, the experimental systems and designs used
in different studies probably influence the cellular responses.
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Two distinct approaches of experimental mouse genetics
have been used to explore the specific contributions of
β-catenin in the transformation of mammary epithelium.
These experiments unveiled two faces of β-catenin: its
ability to elicit adenocarcinomas, and its ability to induce
transdifferentiation into squamous metaplasias (Table 1).
The ability of β-catenin to induce different reactions of
cells might be the result of its concentration, the time of its
activation and the cellular context.
Models on the stage
The role of β-catenin has been investigated using two dis-
tinct approaches of experimental mouse genetics. In the
first set of experiments, transgenes encoding stabilized
β-catenins were expressed under control of the mouse
mammary tumor virus-long terminal repeat (MMTV-LTR), a
control element that is active in a variety of epithelial and
hematopoietic cells. This approach provided information
on the cell-specific function of β-catenin when expressed
ectopically. The second approach relied on the Cre-loxP
recombination system to establish mice in which the
endogenous β-catenin gene was altered to produce a sta-
bilized/activated protein. This experimental design ensures
that the expression of the stabilized β-catenin remains
under the control of its own genetic control elements.
Activated β β-catenin can induce
adenocarcinomas in mouse mammary tissue
Two studies have demonstrated that the expression of a
gene, encoding an N-terminal truncated β-catenin, under
the control of an MMTV-LTR induces adenocarcinomas in
the mammary gland [9,10]. These investigators expressed
β-catenin molecules from which either 89 (∆N89β-catenin)
or 90 (∆N90β-catenin) N-terminal amino acids had been
deleted, which resulted in their stabilization and activation.
In a high expressing ∆N89β-catenin line, all females devel-
oped adenocarcinomas of the breast within approximately
4 months of age [10]. In MMTV-∆N90β-catenin mice [9],
the emerging hyperplasias and adenocarcinomas
appeared to be similar to those observed in mice ectopi-
cally expressing Wnt-1 and Wnt-10b under a similar
MMTV-LTR [11,12]. Adenocarcinomas of the breast were
detected after 4 months of age but the progression
appeared to be slower. This could be the result of strain
differences or expression levels at early stages. Both
groups concluded that Wnt-induced mammary tumorigen-
esis is mediated by β-catenin, which directly targets and
activates the expression of the cyclinD1 and c-myc genes.
Furthermore, this suggests that the β-catenin–cyclin
D1/c-myc signaling pathway is common to colon tissue
[13–15] and to mammary tissue in its ability to induce
neoplasias. Interestingly, ∆N89β-catenin also induced pre-
cocious lobuloalveolar development and differentiation in
males and in virgin females, which resembled a develop-
mental state normally seen during pregnancy [10]. This
obviously raises another curtain and portrays β-catenin as
a molecule that can alter the differentiation state of a cell.
Activated β β-catenin can alter the fate of
mammary epithelium
In the second genetic approach to investigate the role of
activated β-catenin in mammary epithelium, the endoge-
nous gene was altered using the Cre-loxP recombination
system to produce a stabilized protein [16]. Exon 3 of the
endogenous β-catenin gene, which encodes amino acids
5–80, was flanked by loxP sites (∆Exon3 β-catenin mice)
[17]. Two distinct transgenic mice expressing Cre recom-
Table 1
Gain-of-function of β β-catenin signaling
Organ Phenotype References
Intestine Polyps Harada et al. [17]
Skin Development of extra hair Gat et al. [33]
follicles, hair tumor
Mammary gland Adenocarcinomas Imbert et al. [10]
Michaelson and
Leder [9]
Transdifferentiation, Miyoshi et al.
squamous metaplasias [16,18]
Liver No neoplasias Harada et al. [40]
Prostate Epithelial neoplasias Gounari et al. [39]
Squamous transdifferentiation Unpublished data
Salivery gland Squamous metaplasias Gounari et al. [39]
Harderian gland Squamous metaplasias
Tooth Odontoma
Table 2
Loss-of-function of β β-catenin signaling
Organ Phenotype Reference
Mesoderm No mesoderm, Haegel et al. [3]
patterning no head structure
Huelsken et al. [4]
Body axis Absence and/or mislocation Huelsken et al. [4]
of anterior markers at
embryonic day 5.5
Skin Stem cells fail to differentiate Heulsken et al. [35]
into follicular keratinocytes,
but adopt an epidermal fate
Brain and Brain malformation and failure
craniofacial of craniofacial development Brault et al. [5]
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binase were used for the deletion of exon 3, which results
in the translation of a stabilized β-catenin. While Cre
expression in whey acidic protein-Cre (WAP-Cre) trans-
genic mice occurs in differentiating mammary epithelium
at around mid pregnancy, expression in MMTV-Cre trans-
genic mice was already observed in ductal epithelium prior
to puberty.
Although it was predictable that these mice should have
developed the same lesions as observed in the transgenic
mice described earlier, the outcome was surprisingly dif-
ferent. No adenocarcinomas were observed within
6 months after stabilizing β-catenin in ∆Exon3  β-catenin
mice [16]. Instead, extensive hyperplasias and metaplasias
were detected at very early stages. Although the WAP
gene promoter is activated during the estrus cycle, this did
not result in the establishment of prominent lesions.
Around days 10–12 of pregnancy, the WAP-Cre trans-
gene is efficiently activated, and hyperplasias and squa-
mous metaplasias were observed at day 15 of pregnancy.
The histological features included ghost cells and fully ker-
atinized structures, which are reminiscent of epidermal dif-
ferentiation.
The molecular character of these cells was established
with immunohistochemical markers, and it was determined
that mammary secretory cells expressing stabilized
β-catenin lose their differentiation and acquire the fate of
epidermis. Markers predictive of mammary epithelium,
such as NKCC1 and Npt2b, were lost and indicators of
early epidermal differentiation, such as cytokeratin 1, were
acquired. This suggested that mammary epithelium has a
latent program in place to alter its fate to epidermal cells,
which can be triggered by β-catenin.
Why does activated β β-catenin induce two
different phenotypes?
On the face of it, the expression of a stabilized β-catenin
under the control of a transgenic promoter or its own pro-
moter should induce similar physiological consequences;
after all, it is the same molecule (Fig.1). It can especially be
predicted that ∆Exon3  β-catenin and ∆N89β-catenin/
∆N90β-catenin are expressed in the same cell type; namely,
the secretory epithelium and not the myoepithelium.
However, there are some fundamental differences in the
experimental design. First, the amount of β-catenin will be
very different because the respective genes were con-
trolled by different promoters. The ∆N89β-catenin and
∆N90β-catenin transgenes were under control of a
MMTV-LTR and their expression most probably exceeded
that of the endogenous gene. Even the low expressing line
with one copy of the transgene developed adenocarcino-
mas, although with a longer delay. On the other hand, the
∆Exon3 β-catenin gene is under control of its endogenous
promoter. The accumulated amounts of ∆Exon3 β-catenin
may be sufficient to induce metaplasias but be insufficient
to cause adenocarcinomas.
However, expression levels may not be the only reason
for the observed differences. While the deletion of
exon 3  results in the loss of amino acids 5–80, the
∆N89β-catenin/∆N90β-catenin mutants lose an additional
15 amino acids. It is possible that these additional amino
acids could contribute to the observed changes (i.e. their
loss could contribute to the formation of adenocarcino-
mas). Although the nature of this difference is not known,
we can hypothesize that the two β-catenins exhibit differ-
ent interactions with other signaling molecules.
Other transgenic mouse models with an
activated canonical Wnt signaling pathway
It is established that β-catenin is a central molecule of the
Wnt signaling pathway, and a number of transgenic mice
have been produced in which different arms of this
pathway have been activated/repressed. A comprehensive
study using these mice established that both adenocarci-
nomas and epidermal transdifferentiation can be induced
[18,19]. Clearly, the disruption of the Wnt signaling
pathway at any level (Wnt-10b, dominant-negative glyco-
gen synthase kinase 3β [GSK3β], ∆Exon3 β-catenin, ade-
nomatous polyposis coli [APC] and cyclin D1) [18,19] can
induce hyperplasias, adenocarcinomas and squamous
metaplasias in mammary tissue (Fig.2).
APC is a key molecule in the degradation pathway of
β-catenin, and loss of APC function leads to the stabiliza-
tion of β-catenin [20,21]. Gallagher and colleagues
recently established mice in which the APC gene had
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Figure 1
Activated β-catenin altered the fate of epithelial cells. In skin, activated
β-catenin induced hair follicles and tumors. In mammary epithelia,
activated β-catenin could induce adenocarcinomas (MMTV-∆N89),
squamous metaplasias (WAP/MMTV-∆Exon3) or both (MMTV-∆N90).
MMTV, mouse mammary tumor virus; WAP, whey acidic protein.66
been inactivated specifically in mammary epithelium using
the Cre-loxP recombination system [22]. Exon 14 of the
Apc gene was deleted by a Cre transgene under the
control of the ovine β-lactoglobulin gene promoter. The
observations from this study are directly relevant to the
∆Exon3 and ∆N89/∆N90  β-catenin mouse models
[9,10,16,22]. Inactivation of Apc led to the development
of metaplasias with concurrent β-catenin activation. No
adenocarcinomas were observed. Mice that lack both Apc
and Tcf-1 develop acanthoma between 3.5 and 8 weeks
of age [22], which display high levels of cytoplasmic and
nuclear  β-catenin. These results demonstrate synergism
between Apc and Tcf-1, and the combined loss leads to
distinct neoplastic lesions. Furthermore, they support a
previous notion on the threshold levels of β-catenin and a
contextual dependency of β-catenin function. The fre-
quency and degree of metaplasias were very different in
the various transgenic models, but a common denomina-
tor (with the exception of cyclin D1 transgenic mice) was
the accumulation of β-catenin.
Other actors supporting β β-catenin activation
Besides the canonical Wnt signaling pathway, many
players cooperate in the activation of β-catenin. For
example, the epidermal growth factor receptor, erbB-2,
c-met and Ron [23–26] can trigger tyrosine phosphoryla-
tion of β-catenin and can cause its nuclear translocation.
Precenilin 1 is known as a cause of early onset familial
Alzheimer’s disease, and it was suggested to be involved
in the degradation machinery of β-catenin, similar to axin
[27]. Notably, a protein kinase A–precenilin 1–GSK3
complex may be functionally equivalent to the casein
kinase 1–axin–GSK3 complex [27,28]. Precenilin 1-null
mice exhibit embryonic lethality, but a rescue with a spe-
cific transgene revealed skin lesions. In precenilin 1-null
skin,  β-catenin accumulated and was correlated with
hyperplasia without evidence of malignancy [27,29].
Although inhibitor of nuclear factor kappa B kinases (IKKα
and IKKβ) interacted with and phosphorylated β-catenin,
these two kinases exhibit different effects for β-catenin
signaling [30]. While IKKα increased β-catenin-dependent
gene expression, IKKβ decreased it. Expression of casein
kinase 2α (CK2α) under the control of a MMTV-LTR also
induced adenocarcinomas and squamous metaplasias
[18,19,31]. Although the role of CK2 in the Wnt signaling
pathway has not been fully defined, it is known that CK2α,
the catalytic subunit of CK2, and β-catenin are increased
in mammary epithelia after the forced expression of Wnt-1
[32]. Precenilin 1-null cells still employ a casein kinase
1–axin–GSK3 pathway to degrade β-catenin, and CK2α
transgenic mice displayed adenocarcinomas and squa-
mous metaplasias. These results suggest that these mole-
cules could be able to control the amount of β-catenin and
therefore may explain the different phenotypes that were
observed. It is further possible that these or other mole-
cules differentially communicate with the various stabilized
β-catenin molecules, and thus elicit distinct cellular
responses.
β β-Catenin and epidermis differentiation
What is the mechanistic basis underlying the transdifferen-
tiation process of mammary epithelia into the epidermal
lineage? Over the past few years β-catenin has emerged
as a prominent executor that can define lineages in the
skin. It had already been shown in 1998 that stabilized
β-catenin can induce new hair follicles and trichofollicu-
loma-like tumors in skin [33]. Follicular (hair) and epidermal
stem cells are located in the bulge region [34]. Huelsken
and colleagues demonstrated that, in the absence of
β-catenin, stem cells can differentiate into the epidermal
lineage but not into the hair follicular lineage [35].
It is possible that β-catenin in stem cells cooperates with
LEF-1 and/or TCF-3 to control cell fate decision [36]. Sur-
prisingly, expression of ∆N Lef-1, which cannot bind to
β-catenin, in skin caused the development of squamous epi-
dermal cysts and skin tumors [37]. This observation was
supported by experiments in which the stabilization of
β-catenin lacking the C-terminal transactivation domain
caused the promotion of hair fates in epidermis and an epi-
dermal fate in hair cells [38]. Although β-catenin plays an
important role in hair fate, the molecular signals causing the
transdifferentiation process into squamous metaplasias
remain elusive. Taken together, these experiments suggest a
complex role for β-catenin in that it can alter cell fate during
the establishment of a specific lineage, and that this feature
is dependent on the cooperation of cell-specific factors.
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Figure 2
Canonic Wnt signaling pathway molecules can induce a similar
phenotype. When each molecule in the canonic Wnt signaling
pathway was activated, they could induce hyperplasias,
adenocarcinomas and squamous metaplasias. GSK3, dominant
negative glycogen synthase kinase 3β; APC, adenomatous polyposis
coli; P, phosphorylated form; dsh, dishevelled.67
Conclusion: the cell specificity of β β-catenin
signaling
Mutations in the β-catenin signaling pathway have been
associated with a number of different cancers, notably that
of the colon. No clear link between an activated β-catenin
signaling pathway and breast cancer has been estab-
lished. However, an activation of the Wnt/β-catenin
pathway in mammary tissue of transgenic mice can result
in neoplasias and adenocarcinomas, demonstrating that
these cells can read and interpret the respective signals.
In contrast, the development of squamous cysts in human
disease could be the result of β-catenin signaling as has
been observed in transgenic mice.
Expression of stabilized β-catenin has been targeted to
many organs in the mouse, and a cell-specific response is
now appreciated. Clearly, cells from different germ layers
respond to the signaling cues of activated β-catenin.
Gounari and colleagues used the ∆Exon3 β-catenin mouse
model and stabilized the protein in mammary tissue,
preputial gland, prostate, salivary gland, harderian gland,
and tooth [39] (Table1). Their experiments suggest that
cells derived from both the endoderm and the ectoderm
can differentiate into epidermis (except tooth). Stabilization
of  β-catenin in the intestine caused the development of
polyps [17], and neoplasias were observed in the prostate
[39]. Similarly, the activation in liver cells did not result in
neoplastic foci and only caused hepatomegaly [40]. Taken
together, the control of cell specification by β-catenin is not
confined to the establishment of the embryonic body plan,
but also to cells in the adult.
β-catenin performs different roles on many stages. A
burning question focuses on the identity of the supporting
actors that confer the specificity. Equally important, the
nature of the downstream mediators and executors
remains to be discovered. Willert and colleagues recently
published an intriguing study from human teratocarcinoma
cells that were cultured with Wnt-3A [41]. The 5-fold to
10-fold elevation of β-catenin levels resulted in the induc-
tion of approximately 50 genes, some of them having the
ability to block or revert the differentiation [41]. As our
understanding of the relevant signaling pathways
deepens, we will understand how β-catenin can slip into
so many costumes and adopt so many different roles.
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